TLR3 詳細
Molecule Name
Toll like receptor 3
分子の別称
TLR3,CD283,IIAE2
Drug Development Progress
治験薬の数7
市販薬剤の数1
研究＆開発段階Approved
ターゲットの別称
CD283，TLR3，Toll Like Receptor 3，Toll-Like Receptor 3，CD283 Antigen，IIAE2
TLR3 製品リスト
You Have Viewed 0 Of 0 Results
治験薬に関する情報
| 英語名 | 研究コード | 研究開発ステージ | 会社 | 適応症 | 臨床試験 |
|---|---|---|---|---|---|
| TR-987 | Z-101; GLYC-101; MG-3601; TR-987 | Phase 3 Clinical | Kazia Therapeutics | Varicose Ulcer; Varicose Veins; Wounds and Injuries | 詳細 |
| Monovalent norovirus Vaccine (Vaxart) | VXA-G1-1-NN; VXA-G1.1-NN | Phase 2 Clinical | Vaxart Inc | Norovirus Infections | 詳細 |
| Poly ICLC (Oncovir) | Phase 2 Clinical | National Institutes Of Health, Oncovir Inc | Breast Neoplasms; Carcinoma, Basal Cell; Carcinoma, Intraductal, Noninfiltrating; Carcinoma, Merkel Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Colorectal Neoplasms; Coronavirus Disease 2019 (COVID-19); Esophageal Neoplasms; Glioma; HIV Infections; Low-grade Glioma; Lymphoma, B-Cell; Lymphoma, T-Cell; Melanoma; Mesothelioma; Metastatic breast cancer; Neoplasms; Osteosarcoma; Pancreatic Neoplasms; Prostatic Neoplasms; Sarcoma; Stomach Neoplasms; Urinary Bladder Neoplasms | 詳細 | |
| BO-112 | BO-112 | Phase 2 Clinical | Highlight Therapeutics SL | Carcinoma, Basal Cell; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Dermatofibrosarcoma; Esophageal Neoplasms; Fibrosarcoma; Histiocytoma, Malignant Fibrous; Leiomyosarcoma; Liposarcoma; Melanoma; Neoplasms; Neurofibrosarcoma; Rhabdomyosarcoma; Sarcoma; Sarcoma, Synovial; Stomach Neoplasms | 詳細 |
| Monovalent norovirus Vaccine (Vaxart)/VXA-G2-4-NS | VXA-NVV-201 | Phase 2 Clinical | Vaxart Inc | Norovirus Infections | 詳細 |
| CNTO-5 | CNTO-5 | Phase 1 Clinical | Morphosys Ag | Inflammation | 詳細 |
| PGV-001 | PGV-001 | Phase 1 Clinical | Genentech Inc, Icahn School Of Medicine At Mount Sinai | Neoplasms; Urologic Neoplasms | 詳細 |
市販薬剤に関する情報
| 英語名 | 研究コード | 研究開発ステージ | 会社 | オリジナル製品名 | 最初に承認をした国 | 最初の適応症 | 最初に承認を受けた会社 | 承認された日付 | 適応症 | 臨床試験 |
|---|---|---|---|---|---|---|---|---|---|---|
| Rintatolimod | AMP-516; AMP-518 | Approved | Hemispherx Biopharma Inc | Rintamod, Ampligen | Argentina | Fatigue Syndrome, Chronic | Hemispherx Biopharma Inc | 2017-01-01 | Breast Neoplasms; Breast Neoplasms, Male; Colorectal Neoplasms; Fatigue Syndrome, Chronic; HIV Infections; HIV Seropositivity; Influenza, Human; Mesothelioma; Ovarian Neoplasms; Pancreatic Neoplasms; Peritoneal Neoplasms; Post-Acute COVID-19 Syndrome | 詳細 |